Warning: file_get_contents(https://multipass.sense-studios.com/check_token/-1?url=%2Fspecialisation%2Foncology%2Fsecond-line-sacituzumab-govitecan-improves-survival-in-metastatic-tnbc%2F&agent=CCBot%2F2.0+%28https%3A%2F%2Fcommoncrawl.org%2Ffaq%2F%29&name=dev.mc.sense-studios.com&ip=34.225.194.102&categories=Conference+Report+Article%7CBreast+Cancer%7CBreast+Cancer%7COncology%7CESMO+2020): failed to open stream: HTTP request failed! HTTP/1.1 500 Internal Server Error in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/header-tokenaccess.php on line 114

Notice: Trying to get property 'status' of non-object in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/header-tokenaccess.php on line 117

Notice: Trying to get property 'access_type' of non-object in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/header-tokenaccess.php on line 123
Second-line sacituzumab govitecan improves survival in metastatic TNBC - Medical Conferences

Home > Oncology > ESMO 2020 > Breast Cancer > Second-line sacituzumab govitecan improves survival in metastatic TNBC

Second-line sacituzumab govitecan improves survival in metastatic TNBC


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ESMO 2020
In pretreated metastatic TNBC patients, standard of care chemotherapy is associated with low objective response rates (ORRs) and short median progression-free survival (PFS). Results of the phase 3 ASCENT trial show improved ORR rates, and improved survival.

Sacituzumab govitecan is an antibody-drug conjugate composed of an anti-Trop-2 antibody coupled to SN-38, the active metabolite of irinotecan. Trop-2 is expressed in all subtypes of breast cancer and linked to a poor prognoses. SN-38 is released both intracellularly and in the tumour microenvironment. Based on the results of a phase 1/2 trial, the FDA recently approved sacituzumab govitecan for treatment of refractory, metastatic TNBC [1].

In the phase 3 ASCENT study, 468 metastatic TNBC patients who had relapsed or had refractory disease after ≥2 prior chemotherapies in the advanced/metastatic setting were randomised 1:1 to sacituzumab govitecan (10 mg/kg IV on day 1 and 8, every 3 weeks) or single-agent chemotherapy of physicians’ choice (capecitabine, eribulin, vinorelbine, or gemcitabine) until disease progression/unacceptable toxicity [2].

Sacituzumab govitecan compared with chemotherapy significantly improved both median PFS (5.6 vs 1.7 months; HR 0.41; P<0.0001) and median overall survival (12.1 vs 6.7 months; HR 0.48; P<0.0001; see Figure). ORR was 35% for sacituzumab govitecan versus 5% for chemotherapy (P<0.0001). A benefit was observed across all subgroups.

In the safety population (n=482), treatment-related grade ≥3 adverse events were neutropenia (51% vs 33%), diarrhoea (10.5% vs <1%), anaemia (8% vs 5%), and febrile neutropenia (6% vs 2%).

Figure: Overall survival in the phase 3 ASCENT trial [2]


  1. Bardia A, et al. N Engl J Med. 2019;380:741-751.

  2. Bardia A. et al. ASCENT: A randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC). ESMO 2020 Virtual Meeting, abstract LBA17.




Posted on